|Bid||65.00 x 1000|
|Ask||65.89 x 1100|
|Day's Range||65.73 - 67.35|
|52 Week Range||29.27 - 100.77|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 01, 2023 - Nov 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.47|
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
In a striking contrast of fortunes in the Exchange-Traded Fund (ETF) market on Friday, the Uranium ETF outperformed its peers, while the ARK Genomic Revolution ETF struggled.
SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party.
Over the past five years, Exact Sciences (NASDAQ: EXAS) hasn't delivered great returns. Exact Sciences develops cancer diagnostic tests. It is best known for its at-home, noninvasive colorectal cancer screening option, Cologuard.